Article info

Download PDFPDF

Original research
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

Authors

  1. Correspondence to Dr Robert J Motzer; motzerr{at}mskcc.org
View Full Text

Citation

Motzer RJ, Escudier B, McDermott DF, et al
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

Publication history

  • Accepted May 22, 2020
  • First published July 12, 2020.
Online issue publication 
July 12, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.